Spruce Biosciences, Inc.
SPRB
$55.11
$2.344.43%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -90.18% | -86.43% | -71.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -90.18% | -86.43% | -71.27% |
| Cost of Revenue | -77.93% | -70.65% | 2.26% | -10.66% | -2.29% |
| Gross Profit | 76.47% | 67.18% | -24.92% | -11.04% | -16.14% |
| SG&A Expenses | 12.64% | 2.37% | -6.81% | -3.66% | 3.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.14% | -53.14% | -0.31% | -8.93% | -1.03% |
| Operating Income | 54.99% | 49.04% | -14.44% | -6.69% | -12.80% |
| Income Before Tax | 32.93% | 26.53% | -21.44% | -12.13% | -18.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.93% | 26.53% | -21.44% | -12.13% | -18.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.93% | 26.53% | -21.44% | -12.13% | -18.61% |
| EBIT | 54.99% | 49.04% | -14.44% | -6.69% | -12.80% |
| EBITDA | 55.43% | 49.04% | -14.53% | -6.75% | -12.87% |
| EPS Basic | 61.31% | 44.62% | -17.55% | -8.58% | -15.14% |
| Normalized Basic EPS | 67.46% | 50.94% | -17.55% | -8.58% | -15.14% |
| EPS Diluted | 61.31% | 44.62% | -17.55% | -8.58% | -15.14% |
| Normalized Diluted EPS | 67.46% | 50.94% | -17.55% | -8.58% | -15.14% |
| Average Basic Shares Outstanding | 70.82% | 38.06% | 4.67% | 4.47% | 2.92% |
| Average Diluted Shares Outstanding | 70.82% | 38.06% | 4.67% | 4.47% | 2.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |